Fresenius Medical Care stock
Price history
−5.10% over the period1 year: from €39.62 (November 20, 2025) to €37.60 (November 20, 2026), −5.10%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €37.60 |
| October 30, 2026 | €40.40 |
| September 30, 2026 | €39.57 |
| August 31, 2026 | €39.45 |
| July 31, 2026 | €44.45 |
| June 30, 2026 | €39.60 |
| May 29, 2026 | €37.19 |
| April 30, 2026 | €38.61 |
| March 31, 2026 | €38.57 |
| February 27, 2026 | €39.45 |
| January 30, 2026 | €37.91 |
| December 30, 2025 | €40.76 |
| November 28, 2025 | €41.25 |
| November 20, 2025 | €39.62 |
At a glance
The company
Provides dialysis treatment and related services for patients with renal disease, plus manufactures dialysis equipment and renal pharmaceuticals
Latest results
Quarter to September 30, 2026 · EPS €1.11 (estimate €1.06)
TickerLandia's take on Fresenius Medical Care
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 11 vs a median of 17 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 12 vs 18 (−30%) in a group of 10.
- Strong point: Dividend (80/100 in its group). Weak point: Growth (11/100).
- “Value traps” (Germany): No. 9 of 12.
- “Below historical valuation” (Germany): No. 10 of 20.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−18.08% from the 52-week high
Analysts · 17 analysts
Average target€39.39+4.76% vs. price
Buy 4 · Hold 6 · Sell 7 · Hold
TickerLandia Fingerprint: Fresenius Medical Care
Compared with similar companies: very low growth and very low price.
Financials and price compared with 19 companies in the medical care facilities industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low13
How much it costs relative to what it produces.
Metric Value Position in group Price/book 0.76 3 Price/sales 0.50 3 P/E (trailing 12 months) 12.3 19 Forward P/E 9.87 19 EV/EBITDA 7.61 18 Profitabilitylow23
How much it earns on revenue and capital.
Metric Value Position in group ROE 7.8% 14 ROA 3.9% 18 Gross margin 26.5% 29 Operating margin 10.1% 34 Net margin 4.2% 18 Earnings stabilityhigh62
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.3% 66 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 58 Growthvery low11
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +0.39% 3 Revenue growth (year over year) +1.10% 18 Earnings growth (year over year) −35.40% 13 Financial strengthaverage40
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 0.99 39 Debt/equitycounts in reverse: lower means more financial strength 0.79 58 Net debt/EBITDAcounts in reverse: lower means more financial strength 3.50 29 Interest coverage 4.86 34 Dividendhigh80
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 27 years 92 Dividend yield 4.0% 91 Payout ratio 48.9% 56 Market momentumweak38
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −3.67% 38 Relative strength (6 months) −2.62% 50 Distance from 200-day average −5.42% 37 1-year return −5.10% 29 Risklow33
How much the price swings.
Metric Value Position in group Volatility (60 days) 33.2% 69 Beta (1 year) 0.15 6 Maximum drawdown (12 months) 18.1% 25
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Fresenius Medical Care is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Fresenius Medical Care's P/E today is 11.2, below the median of its last 10 fiscal years (17.2; between 8.78 and 24.1 from 2016 to 2025). Fresenius Medical Care's P/E (trailing 12 months): 12.3, −30% against the median of a group of 10 similar companies (17.6).
Compared with 10 similar companies
| Metric | Fresenius Medical Care | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 12.3 | Low | |
| Forward P/E | 9.87 | Middle | |
| Operating margin | 10.1% | Middle | |
| ROE | 7.8% | Low | |
| Debt/equity | 0.79 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Fresenius Medical Care. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€4.86B
Latest quarter · Q2 2026
Net income
€218.38M
Latest quarter · Q2 2026
Quarterly net margin
4.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €9.76B
- P/E
- 12.3
- EPS
- €3.05
- Volume
- 1.77M
- Daily trading
- €48.43M
- Dividend yield
- 3.96%
- Last ex-dividend on May 22, 2026
How Fresenius Medical Care is changing
All resultsRevenue grew 1.9% a year on average over the last 5 years
Operating margin rose from 7.9% to 9.5%
Returns
Fresenius Medical Care returns with dividends
€1,000 invested in Fresenius Medical Care 5 years ago, on November 22, 2021, would be worth €781 today with dividends reinvested: −21.90% in total, −4.83% per year. On price alone it would be €675 (−32.47%).
| Period | Fresenius Medical Care | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | −4.71% | −1.98% | €953 |
| 6 months | −2.36% | +0.26% | €976 |
| Year to date | −7.75% | +1.28% | €922 |
| 1 year | −1.30% | +6.55% | €987 |
| 3 years | +16.13% | +55.98% | €1,161 |
| 5 years | −21.90% | +53.90% | €781 |
| 10 years | −35.68% | +132.12% | €643 |
Over the last 6 months it has done better than 19% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment
The chart in detail
Fresenius Medical Care: technical analysis
Fresenius Medical Care shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 59.6% below its all-time closing high (€93.00, January 31, 2018).
- Trend
- No clear trend
- RSI (14 sessions)
- 40
- Between 30 and 70
- vs 200-session average
- −5.42%
Support and resistance
Price areas where Fresenius Medical Care has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€40.75+8.37%9 touches, last on September 28, 2026
- Resistance€39.04+3.83%5 touches, last on June 30, 2026
- Resistance€38.21+1.63%5 touches, last on November 3, 2026
- Last price€37.60
- Support€37.03−1.53%2 touches, last on March 23, 2026
- Support€35.68−5.11%3 touches, last on October 8, 2026
Volatility and risk
Over the last year it has moved little with the DAX.
- Beta (1 year) vs DAX
- 0.15
- Volatility (60 sessions, annualised)
- 33.2%
- Largest fall in the last year
- −18.15%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Fresenius Medical Care: seasonality
Average monthly price change over 30 years
Over the last 30 years, the strongest month for Fresenius Medical Care has been November: +5.58% on average, positive in 19 years out of 30. The weakest has been August: −2.80% on average, positive in 9 years out of 30.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.83% | +1.21% | 16 of 30 |
| February | +0.04% | +0.30% | 15 of 30 |
| March | +1.28% | +0.91% | 19 of 30 |
| April | +1.98% | +0.51% | 16 of 30 |
| May | −1.39% | −1.13% | 12 of 30 |
| June | +0.65% | +1.76% | 19 of 30 |
| July | +0.46% | +1.12% | 18 of 30 |
| August | −2.80% | −2.52% | 9 of 30 |
| September | −0.37% | +1.19% | 19 of 30 |
| October | −1.23% | −1.55% | 12 of 30 |
| November | +5.58% | +3.14% | 19 of 30 |
| December | +0.13% | +0.72% | 16 of 30 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Fresenius Medical Care and its competitors
Revenue of EUR 19.6 billion in the fiscal year ended 31 December 2025 comes from a business centred on dialysis for people with renal diseases in Germany, the United States and other countries. Dialysis treatment is delivered through a network of outpatient clinics, with laboratory and diagnostic services, patient support and home delivery of supplies, while US hospitals contract the group for care of end-stage renal disease and acute kidney failure patients.
- Headquarters
- Bad Homburg, Germany
- Employees
- 106,291
- Founded
- 1996
- Chief executive
- Helen Giza
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Fresenius Medical CareFME | $10.72B | 10.1% | 12.3 | −2.36% |
| MedicoverMCOV.B | $3.82B | 7.4% | 38.3 | +19.86% |
| FreseniusFRE | $31.8B | 9.9% | 18.4 | +27.91% |
| Spire Healthcare GroupSPI | $1.3B | 7.6% | — | +12.90% |
| TerveystaloTTALO | $830.61M | 8.9% | 13.0 | −27.00% |
| Universal Health ServicesUHS | $10.34B | 10.9% | 7.51 | +9.20% |
Same industry or related industries, similar size. Compare Fresenius Medical Care with its competitors · Full profile
